111 related articles for article (PubMed ID: 10574618)
1. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
[TBL] [Abstract][Full Text] [Related]
2. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
[TBL] [Abstract][Full Text] [Related]
4. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
6. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
8. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.
Witt PL; Storer BE; Bryan GT; Brown RR; Flashner M; Larocca AT; Colby CB; Borden EC
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):191-200. PubMed ID: 8471593
[TBL] [Abstract][Full Text] [Related]
10. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta.
Liberati AM; Horisberger MA; Palmisano L; Astolfi S; Nastari A; Mechati S; Villa A; Mancini S; Arzano S; Grignani F
J Interferon Res; 1992 Oct; 12(5):329-36. PubMed ID: 1431312
[TBL] [Abstract][Full Text] [Related]
11. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
Rothuizen LE; Buclin T; Spertini F; Trinchard I; Munafo A; Buchwalder PA; Ythier A; Biollaz J
J Neuroimmunol; 1999 Sep; 99(1):131-41. PubMed ID: 10496186
[TBL] [Abstract][Full Text] [Related]
12. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
Sega S; Wraber B; Mesec A; Horvat A; Ihan A
Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.
Buchwalder PA; Buclin T; Trinchard I; Munafo A; Biollaz J
J Interferon Cytokine Res; 2000 Oct; 20(10):857-66. PubMed ID: 11054273
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.
Williams GJ; Witt PL
J Interferon Cytokine Res; 1998 Nov; 18(11):967-75. PubMed ID: 9858319
[TBL] [Abstract][Full Text] [Related]
15. [Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations].
Sokolova TM; Lopatina OA; Nosik NN; Cheshik SG
Biull Eksp Biol Med; 1993 Jun; 115(6):633-4. PubMed ID: 7690616
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
17. Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing.
Martin PL; Vaidyanathan S; Lane J; Rogge M; Gillette N; Niggemann B; Green J
J Interferon Cytokine Res; 2002 Jun; 22(6):709-17. PubMed ID: 12162883
[TBL] [Abstract][Full Text] [Related]
18. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.
Files JG; Hargrove D; Delute L; Cantillon M
J Interferon Cytokine Res; 2007 Aug; 27(8):637-42. PubMed ID: 17784815
[TBL] [Abstract][Full Text] [Related]
19. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
Sturgill MG; Rashidbaigi A; Liao MJ; Zhao XX; Hua J; Trout R; Knill JR; Grasing KW
J Clin Pharmacol; 2000 Jun; 40(6):606-15. PubMed ID: 10868311
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
